FindingsScience read/Oncology/Small Molecule RK-251 Was Tested Against One Cancer Cell Line. The Problem It Was Built to Solve Is Bioavailability. Athithi Verma· 25 August 2026· 2 min read· Synopulse What they did A research article in the Journal of Medicinal Chemistry, published 23 July 2026 across pages 17342 to 17365. Kesarwani and colleagues at IIT … Read more
Serious adverse reactions ran at 38% in the combination trial against 26% in the monotherapy trial. Same drug, same line, different companion.
First and only is not the same as available. One authorisation covers 30 jurisdictions, each of which now prices the drug separately.
QuickAccess read/Endocrine & Metabolic/Peptide NICE Backed a Weekly Insulin Before It Has a Licence, Then Told Prescribers to Pick the Cheapest Option Athithi Verma· 25 August 2026· 2 min read· Synopulse NICE published final draft guidance recommending insulin efsitora alfa (Onswik), from Eli Lilly, for adults with type 2 diabetes. Given once weekly by pre-filled … Read more
https://synopulse.com/wp-content/uploads/2026/08/Roche-Paid-190-Million-Up-Front-on-a-2.3-Billion-Headline-for-a-Phase-1-Obesity-Asset.webp
One drug reached review only because payers filed for a manufacturer that had not. The other was recommended on evidence the committee called inconclusive.
A biosimilar licence used to be the scarce asset. In ustekinumab it is the entry ticket, and the returns go to whoever solves supply and device.
Same drug, same week, two Asian markets. The regulator approved on progression-free survival. The payer funded only the regimen with overall survival data.
Three glioblastoma patients returned identical MGMT results and behaved differently on a barrier chip. The sample size is three, and the framing still matters.
Pasatru’s flare benefit is clinician-assessed only. GENGLYCOS is indicated to reduce cornstarch intake. Two firsts, both measured a step from the patient.